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42 days. Specimens were collected at days 1,3,7,21,42,
and 90. IH and SMCp were measured at the fistula site as
well as in the artery and vein proximal and distal to the
fistula.
Results: IH was first noted at day 3 and significantly
increased through day 90 at all locations in the non-
oxygen supplemented groups. There was no significant
IH noted in the O2 supplemented groups at any location
or any time point Table). SMCp was noted at Day 3
through Day 21 in the non-oxygen supplemented group
while almost no SMCp was noted in the O2 supple-
mented groups at any location or timepoint.
Conclusions: Without O2 supplementation SMCp
begins at day 3 and is no longer noted at day 21 after
creation of an AVF while IH begins by day 3 and increases at
least through day 90 after creation of an AVF. 42 days of 30%
supplementalO2 inhibits both IH and SCMp after creation of
an AVF. This data suggests a role for short-term administra-
tion of low-dose O2 to prevent both IH and SMCp after
creation of an AVF prolonging fistula patency and function.
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Ischemia Mediates Myogenic Progenitor Cell Dysfunc-
tion
Matthew Fincher, David Abraham, George Hamilton,
Daryll Baker, Janice Tsui. Royal Free Hospital, London,
United Kingdom
Objectives: Treatment options for critical limb isch-
emia (CLI) are limited. Recent evidence has suggested
that even with successful revascularisation, patients often
show little functional improvement. This has been attrib-
uted to a musculopathy that occurs in CLI. Myogenic
progenitor satellite cells (SCs) provide skeletal muscle
with an intrinsic ability to regenerate. It has been shown
that there is an increase in SCs in ischemic muscle,
however their function in ischemia is poorly understood
and we hypothesize that ischemia has a detrimental effect
on SC function.
Methods: Gastrocnemius muscle biopsies were taken
from CLI patients and compared with non ischemic
control biopsies. The phenotypical changes and fre-
quency of satellite cells were investigated using PAX 7
immunohistochemistry and western blot. C2C12 myoblasts
were used in vitro, to investigate the effect of ischemia on
muscle progenitor cell function. Myoblasts were exposed to
simulated ischemia for 24, 48 and 72hrs. Proliferation rates
were assessed using an MTT assay. Differentiation and apo-
ptosis were assessed byMYOD and cleaved caspase 3 western
blotting respectively.
Results: There is an increased expression of PAX 7 in
CLI muscle biopsies, shown by both immunostaining and
western blot analysis, suggesting an increased number of
SCs in ischemic human skeletal muscle (P.05).Myoblasts
cultured in ischemic conditions demonstrated decreased
cell proliferation, reduced myogenic differentiation (de-
creased MYOD expression), and increased apoptosis (in-
creased cleaved caspase 3 expression).
Conclusions: Despite an upregulation of SCs in isch-
emic tissue, their function is suppressed in ischemic condi-
tions and this may be contributing to the poor functional
recovery of patients post revascularisation. Enhancement of
muscle regeneration in ischemiamay be a useful therapeutic
adjunct in the treatment of CLI.
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The Pro-Proliferative and Anti-Apoptotic Micro-RNA
221 Is Decreased in Vulnerable Carotid Atherosclerotic
Plaques
Hernan A. Bazan, Chasity B. Coleman, Taylor Smith, W
Charles Sternbergh III, T. Cooper Woods. Ochsner Clinic,
New Orleans, LA
Objectives: MicroRNAs (miRs) are a class of recently
discovered noncoding endogenous, small RNAs that neg-
atively regulate gene expression. miR-221 is associated with
vascular smooth muscle cell proliferation and inhibition of
apoptosis. We aimed to determine whether miR-221 is
decreased in acutely symptomatic as opposed to stable,
asymptomatic carotid plaques.
Methods: Relative changes in gene expression levels
of miR-221 were compared using a commercial real-time
PCR assay and the 

Ct method. All samples were run in
duplicate; mean and standard error were calculated.
One-way ANOVA with Tukey’s test and Pearson’s cor-
relation were used to determine significance between
groups.
Results: Levels of miR-221were quantified from asymp-
tomatic (n16) and symptomatic (n6) carotid
plaques. In order to capture the acute state of plaque
rupture, patients undergoing urgent CEA (n11) for
acute neurologic symptoms were included. The propor-
tion of miR-221 in urgent compared to asymptomatic
carotid plaques was reduced (.30.16 vs. 1.00.44, P
.039) (see figure). Moreover, a decreasing trend in miR-
221 levels was noted in asymptomatic-to-symptomatic-
to-urgent plaques (R.43, P  .013).
Conclusions: Carotid plaque levels of miR-221 are
decreased in patients presenting with acute neurological
symptoms compared to patients with asymptomatic ca-
rotid disease. As miR-221 levels are decreased in rup-
tured (urgent CEA) carotid plaques, we postulate that
loss of miR-221 may be important in the transition of a
stable to an unstable carotid atherosclerotic plaque and
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possible fibrous cap degradation and rupture. *:P 
.039.
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Role of PI3k/Akt Pathway in the Cytoprotective Ef-
fects of Erythropoietin and Derivatives in Ischemic
Human Myotubes
Rebekah Yu, George Hamilton, Daryll Baker, Janice Tsui.
Department of Surgery, University College London, Lon-
don, United Kingdom
Objectives: Erythropoietin (Epo) has tissue-protec-
tive effects following ischemic injury, mediated through
the EpoR-cR heteroreceptor. Having previously shown
presence of the EpoR in human skeletal muscle, we now
aim to show the direct interaction of the EpoR with the
cR. Further, we wanted to determine the cytoprotec-
tive effects of Epo and an Epo-derivative (ARA-290) in a
human in vitro model of skeletal muscle and establish the
role of PI3K/Akt pathway in protecting cells from
apoptosis.
Methods: Gastrocnemius muscle biopsies were ob-
tained from patients with critical limb ischemia and
control samples were obtained from non-ischemic pa-
tients. Co-immunoprecipitation (Co-IP) was performed
to demonstrate heterodimerisation of EpoR with cR.
Human myoblasts were isolated to determine the cyto-
protective effects of Epo and ARA-290 pre-treatment on
myotubes subjected to simulated ischemia. Wortmannin
(PI3k inhibitor) was used to determine the role of PI3k/
Akt pathway in mediating cytoprotection. Western blot
analysis, using the pro-apoptotic marker cleaved
caspase-3 was performed and compared with levels of
Akt and phosphorylated-Akt, using western blot analysis.
Results: EpoR and cR has been demonstrated in
human skeletal muscle. Heterodimerisation of EpoR-cR
was confirmed by Co-IP. Epo and ARA-290 were able to
ameliorate the ischemia-induced apoptosis on isolated
human myotubes. Addition of wortmannin, to ARA-290
or Epo pre-treated cells, abolished the reduction in
apoptosis. Further, a reduction in apoptosis was associ-
ated with an increase in phosphorylated-Akt on western
blot analysis.
Conclusions: EpoR-cR heteroreceptor was demon-
strated in human skeletal muscle. ARA-290 attenuates
apoptosis in ischemic human myotubes suggesting a
potential role in tissue protection during skeletal muscle
injury. We propose that the PI3k/Akt signalling pathway
is involved in mediating this cytoprotection.
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Tracking the Migration of Porcine Mesenchymal Stem
Cells with the MRI Contrast Agent Ferex in an AAA
Model
Rami Tadros, Bhakti Rawal, Karen Briley-Saebo, David
O’Connor, Dan Han, Roger Hajjar, Zahi Fayad, Michael
Marin, Peter Faries. The Mount Sinai School of Medicine,
New York, NY
Objectives: Mesenchymal stem cells (MSC) are being
investigated in a porcine abdominal aortic aneurysm
(PAAA) model for their repair potential. This study uses
MSCs labeled with the MRI contrast agent Ferex to non-
invasively evaluate MSC migration in-vivo.
Methods: MSCs from six pigs were isolated from
bone marrow via Ficoll Paque separation and expanded
in culture. Using a Lentiviral vector, MSC from all six
pigs were labeled with green florescent protein (GFP).
MSCs from four of these pigs were labeled with Ferex
using Poly-L-Lysine, a cationic transfecting agent. These
cells were analyzed for Ferex uptake and viability. Pres-
ervation of the MSC phenotype was confirmed using
cytometry by detecting positive CD90 signals and nega-
tive CD45 and CD117. Transmission electron micros-
copy established that Ferex particles localized to lyso-
somes of labeled cells. MSCs were then injected into the
PAAA. In-vivo MRI was performed at intervals followed
by euthanasia and histologic analysis.
Results: Ferex labeled MSCs were visible at 4, 11,
and 15 days using MRI and the signal loss progressed at
each study interval representing cellular movement (Fig
1). MSC migration and localization were confirmed with
GNP visualization on fluorescence microscopy and im-
munohistochemistry. A correlation between in-vivo
MRI signals and iron deposition was clearly demon-
strated histologically using Perl’s staining.
Fig.
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